Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has hosted a group of Australian interventional cardiology and Transcatheter Aortic Valve Replacement (TAVR) experts at its Malaga facility in Perth, Western Australia.
The interventional cardiologists were given a detailed technical overview of Anteris’ DurAVR™ Transcatheter Heart Valve (THV) technology, including its design, ADAPT® tissue science and the ComASUR™ Transfemoral Delivery System.
Anteris’ Malaga facility manufactures the DurAVR™ THV, a proprietary 3D single-piece leaflet design that mimics a native aortic valve using its ADAPT® tissue technology.
The overview included a tour of the facility to observe the R&D laboratories, ongoing testing and manufacturing operations for Anteris’ clinical trial program.
Physician support
Anteris intends to partner with the clinicians to commercialise the DurAVR™ THV system, as well as to refine the company’s clinical roadmap while also improving investor engagement.
“The company has unlocked the value of its core technology in the past year and physician engagement forms a critical aspect of value delivery. Presenting our Malaga facility in full operational mode demonstrates our deep progress with our DurAVR™ THV program,” Anteris CEO Wayne Paterson said.
“We are continuing to expand our global physician engagement with senior interventional cardiologists and establish long-term collaborative relationships. Physician support and enthusiasm for our product will prove highly beneficial as we continue toward commercialisation and regulatory access goals.
"As an Australian medtech company, it’s critical that we add Australian physicians to our global group of world-leading doctors.”
Turning point
Brisbane-based interventional cardiologist Dr Karl Poon said: “Having had the privilege to have been one of the first to implant DurAVR™ THV and witnessing its superior haemodynamics first-hand, it is now great to see the science, research and ongoing development behind the technology.”
Professor Jayme Bennetts of Flinders University and director of Cardiothoracic Surgery of Flinders Medical Centre added: “With the proven benefits of the ADAPT® tissue technology, we are on the cusp of something very exciting which may solve the issues of tissue valve deterioration. The early haemodynamics of DurAVR™ appear to be superior than currently available valves.”
More than 35,000 ADAPT®-treated tissue devices have been sold and/or supplied globally to treat a wide range of structural heart conditions.